Financial StabilityManagement anticipates a cash runway into 2H26, providing financial stability for upcoming projects and strategic initiatives.
Gene Editing TechnologyPrecision is on track to hit multiple milestones to validate their ARCUS genome editing technology, indicating significant progress and innovation.
Gene Therapy AdvancementsThe lead program PBGENE-HBV is on track to submit a Clinical Trial Application for a first-in-human study, targeting hepatitis B virus, which shows promise for advancing the treatment.